Trial Profile

A single-arm, phase II exploratory clinical study of camrelizumab combined with chemotherapy in neoadjuvant therapy for esophageal cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camrelizumab (Primary) ; Nedaplatin (Primary) ; Paclitaxel (Primary)
Indications Oesophageal cancer; Squamous cell cancer
Focus Therapeutic Use

Most Recent Events

01 Nov 2024 Results (n=32) to predict the response to neoadjuvant camrelizumab plus chemotherapy, published in the Journal of Nuclear Medicine
24 Oct 2023 Results (n=70; From Aug 13, 2021, to Jul 9, 2022) assessing the efficacy and safety of neoadjuvant therapy of camrelizumab, combined with chemotherapy in resectable esophageal squamous cell cancer patients, presented at the 48th European Society for Medical Oncology Congress.
21 Oct 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com